December 2024
Novavax Sells Czech Manufacturing Facility to Novo Nordisk for $200 Million
Novavax, Novo Nordisk, Czech manufacturing facility, cost-cutting, vaccine pipeline development
Cleerly Secures $192M for Heart Attack-Predicting AI Technology
Cleerly, AI, Heart Disease, Coronary Artery Scanning, Funding
Novo Nordisk Invests $409M in New Quality Control Lab in Denmark
Novo Nordisk, quality control lab, Denmark, pharmaceutical investment, biotechnology
Nuvig Therapeutics Secures $161M Series B Funding for Autoimmune Therapy Development
Nuvig Therapeutics, autoimmune therapy, series B funding, Sanofi Ventures, autoimmune diseases, Fc gamma R2B, immunomodulatory therapy
Nuvig Therapeutics Secures $161M Funding for Phase 2 Study in Autoimmune Diseases
Nuvig Therapeutics, autoimmune diseases, Phase 2 study, funding, NVG-2089, Chronic Idiopathic Demyelinating Polyneuropathy (CIDP), recombinant Fc Ab fragments, synthetic manufacturing.
Genmab Exercises Option for Second Commercial License Agreement with Scancell Holdings
Genmab, Scancell Holdings, monoclonal antibody, GlyMab platform, licensing agreement, cancer treatment, immunotherapies
Mitsubishi Tanabe and Dewpoint Therapeutics Collaborate on $480M ALS Treatment Development
ALS treatment, Dewpoint Therapeutics, Mitsubishi Tanabe Pharma Corporation, TDP-43, small molecule condensate modulator, biobucks deal
Healthcare M&A and IRA Price Negotiations: Key Trends to Watch Amidst Political Shifts
Healthcare M&A, IRA Price Negotiations, Medicare Drug Price Negotiation Program, Inflation Reduction Act, Pharmaceutical Industry Trends, Mergers and Acquisitions Outlook 2024
Agenus Announces Strategic Realignment: Focus on Core Programs, Significant Cost Reductions, and Layoffs
Agenus, strategic realignment, layoffs, cost reduction, botensilimab/balstilimab (BOT/BAL), cancer drug development
GSK Invests $546M in Rgenta’s RNA Modulation Technology for Cancer and Other Diseases
GSK, Rgenta, RNA modulation, cancer treatment, pharmaceutical investment